Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.
Board
Ruth E
RE
Cancer Research UK Department Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Ruth.Board@christie-tr.nwest.nhs.uk
Thistlethwaite
Fiona C
FC
Hawkins
Robert E
RE
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002352:Carrier Proteins / Q000235:genetics; D003598:Cytoskeletal Proteins; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D018832:Molecular Chaperones; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins; D003598:Cytoskeletal Proteins; D018832:Molecular Chaperones; C108825:VBP1 protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D040281:Vascular Endothelial Growth Factor Receptor-1